Key result
Endothelial-targeted scFv/TM cuts pulmonary fibrin deposition ~70% and suppresses inflammation in lung injury.
Why the study?
Diverse forms of pulmonary and vascular injury are accompanied by down-regulation of endothelial thrombomodulin, which aggravates tissue injury. The authors postulated that anchoring thrombomodulin to the endothelial surface would restore its protective functions against pulmonary thrombotic and inflammatory injury.
Does endothelial-targeted thrombomodulin fusion protein (scFv/TM) reduce pulmonary thrombosis, inflammation, edema, and mortality compared to nontargeted soluble thrombomodulin in mouse models of lung ischemia-reperfusion and acute lung injury?
Does endothelial-targeted thrombomodulin fusion protein (scFv/TM) reduce pulmonary thrombosis, inflammation, edema, and mortality compared to nontargeted soluble thrombomodulin in mouse models of lung ischemia-reperfusion and acute lung injury?
Anchoring thrombomodulin to pulmonary endothelial PECAM-1 via an scFv fusion construct effectively mitigates thrombosis, inflammation, and mortality in preclinical acute lung injury models without increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for endothelial-targeted thrombomodulin in lung injury; human trials needed before clinical translation.
Rationale Endothelial thrombomodulin (TM) regulates thrombosis and inflammation. Diverse forms of pulmonary and vascular injury are accompanied by down-regulation of TM, which aggravates tissue injury. We postulated that anchoring TM to the endothelial surface would restore its protective functions. Objectives To design an effective and safe strategy to treat pulmonary thrombotic and inflammatory injury. Methods We synthesized a fusion protein, designated scFv/TM, by linking the extracellular domain of mouse TM to a single-chain variable fragment of an antibody to platelet endothelial cell adhesion molecule-1 (PECAM-1). The targeting and protective functions of scFv/TM were tested in mouse models of lung ischemia-reperfusion and acute lung injury (ALI) caused by intratracheal endotoxin and hyperoxia, both of which caused approximately 50% reduction in the endogenous expression of TM. Measurements and Main Results Biochemical assays showed that scFv/TM accelerated protein C activation by thrombin and bound mouse PECAM-1 and cytokine high mobility group-B1. After intravenous injection, scFv/TM preferentially accumulated in the mouse pulmonary vasculature. In a lung model of ischemia-reperfusion injury, scFv/TM attenuated elevation of early growth response-1, inhibited pulmonary deposition of fibrin and leukocyte infiltration, and preserved blood oxygenation more effectively than soluble TM. In an ALI model, scFv/TM, but not soluble TM, suppressed activation of nuclear factor-κB, inflammation and edema in the lung and reduced mortality without causing hemorrhage. Conclusions Targeting TM to the endothelium using an scFv anchor enhances its antithrombotic and antiinflammatory effectiveness in models of ALI.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2009) studied Lung ischemia-reperfusion injury and acute lung injury (ALI). Anti-PECAM-1 single-chain variable fragment/thrombomodulin fusion protein (scFv/TM) vs. Soluble thrombomodulin (sTM, 50 μg) or phosphate-buffered saline (PBS) was evaluated on Pulmonary fibrin deposition and nuclear factor-kappaB (NF-kB) activation (p=<0.05). Endothelial-targeted scFv/TM fusion protein reduced pulmonary fibrin deposition by ~70% in lung ischemia-reperfusion and inhibited NF-kB activation by ~70% in acute lung injury compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: